Results 201 to 210 of about 15,981,489 (330)
The ImproveCareNow Registry: Prediction of different remission rates in pediatric ulcerative colitis
Abstract Objectives Identifying predictors of clinical remission in pediatric ulcerative colitis (UC) will impact the therapeutic approach. We aimed to predict time to first (TFR), corticosteroid‐free (TCSFR, ≥3 months corticosteroid withdrawal), and sustained remission (TSR, ≥6 months).
Jonathan Van Hecke +7 more
wiley +1 more source
Clinical value of the systemic immune-inflammation index in patients with Crohn disease. [PDF]
Yan J +5 more
europepmc +1 more source
Enteral nutritional therapy for induction of remission in Crohn's disease.
N. Narula +5 more
semanticscholar +1 more source
Abstract Accurate pediatric gastrointestinal (GI) diagnosis often depends on integrating clinical, endoscopic, and histopathologic information. We evaluated the impact of weekly face‐to‐face multidisciplinary team (MDT) meetings on diagnosis in children undergoing endoscopy or liver biopsy at a tertiary center.
Emma Dahl +4 more
wiley +1 more source
Impact of sarcopenia on postoperative outcomes and recurrence in patients with Crohn disease: A retrospective cohort study. [PDF]
Yi GH +7 more
europepmc +1 more source
Insurance IQ: Demystifying health insurance for young people with inflammatory bowel disease
ABSTRACT Many adolescents and young adults with inflammatory bowel disease (AYA‐IBD) lack essential health insurance knowledge. We evaluated an electronic health record (EHR)–based educational intervention to improve insurance literacy. From January to August 2025, AYA‐IBD who had completed a health insurance knowledge assessment and had an upcoming ...
Laura Gilligan, Jeannie S. Huang
wiley +1 more source
Human immunodeficiency virus infection mimicking very early onset inflammatory bowel disease
Abstract Very early onset inflammatory bowel disease (VEO‐IBD), defined as diagnosis before 6 years of age, is often associated with immune dysregulation and monogenic etiologies; however, infectious mimics may be overlooked in low‐prevalence regions. We report a 4‐year‐old male with poor weight gain, intermittent diarrhea, elevated fecal calprotectin,
Rasha Abi Radi Abou Jaoudeh +2 more
wiley +1 more source
Abstract Janus kinase inhibitors (JAKi) are increasingly used for refractory inflammatory bowel disease (IBD) in pediatric patients but are associated with significant dermatologic adverse effects. Acneiform eruptions have been reported in up to 30% of adults, with a greater incidence suspected in adolescents.
Tina H. Tran +5 more
wiley +1 more source

